Abstract: Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.
Abstract: The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favourable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.
Type:
Grant
Filed:
October 18, 1996
Date of Patent:
February 15, 2000
Assignee:
Erasums University Rotterdam
Inventors:
Carel A. van Baalen, Albertus D. M. E. Osterhaus
Abstract: Binding of two members of a binding couple reveals epitopes which are revealed only after binding and the monoclonal antibody secreted from the hybridoma cell line CG-10 directed against these epitopes bind to the bound couple at a significantly higher affinity than their binding affinity to either of the two members themselves when not bound to one another.
Type:
Grant
Filed:
January 22, 1999
Date of Patent:
February 1, 2000
Assignee:
Ramot University Authority for Applied Research and Industrial Development Ltd.
Abstract: Novel HIV-2 proviruses, molecular clones, nucleic acids, polypeptides, viruses and viral components are described. The use of these compositions as components of diagnostic assays, as immunological reagents, as vaccines, as components of packaging cells, cell transduction vectors, and as gene therapy vectors is also described.
Type:
Grant
Filed:
June 7, 1996
Date of Patent:
March 16, 1999
Assignee:
The Regents of the University of California
Inventors:
Gunter Kraus, Flossie Wong-Staal, Randy Talbott, Eric M. Poeschla